Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director · Chairman & CEO | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 566,683 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Sale · Disposed 12,000 · Balance 569,683 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2: Sale prices for the transactions reported range from $147.21 to $148.205. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 2 · 2026-10-01 · Sale · Disposed 3,000 · Balance 566,683 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F3: Sale prices for the transactions reported range from $148.23 to $149.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
F2: Sale prices for the transactions reported range from $147.21 to $148.205. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3: Sale prices for the transactions reported range from $148.23 to $149.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $148.63 | $445,879.50 |
DisclosureSEC source: 0001638643-26-000035 · wk-form4_1790973619.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 566,683 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F3 · price: Sale prices for the transactions reported range from $148.23 to $149.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 12,000 | $147.72 | $1,772,628.00 |
DisclosureSEC source: 0001638643-26-000035 · wk-form4_1790973619.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 569,683 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 · price: Sale prices for the transactions reported range from $147.21 to $148.205. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 8,780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001638643-26-000033 · wk-form4_1789165629.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,300 Underlying: Common Stock · 8,780 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 4,230 | $144.81 | $612,546.30 |
DisclosureSEC source: 0001638643-26-000033 · wk-form4_1789165629.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 581,683 Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001638643-26-000033 · wk-form4_1789165629.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 585,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 20:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,408 | $149.38 | $807,856.23 |
DisclosureSEC source: 0001638643-26-000031 · wk-form4_1788379963.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 577,133 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F4 · price: Sale prices for the transactions reported range from $148.96 to $149.94. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 20:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,992 | $148.36 | $1,185,721.89 |
DisclosureSEC source: 0001638643-26-000031 · wk-form4_1788379963.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 582,541 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F3 · price: Sale prices for the transactions reported range from $147.95 to $148.93. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 20:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,600 | $147.51 | $236,013.92 |
DisclosureSEC source: 0001638643-26-000031 · wk-form4_1788379963.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 590,533 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 · price: Sale prices for the transactions reported range from $146.94 to $147.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 21:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 600 | $131.34 | $78,805.98 |
DisclosureSEC source: 0001638643-26-000028 · wk-form4_1785879633.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 592,133 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F4 · price: Sale prices for the transactions reported range from $131.21 to $131.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 21:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,700 | $130.80 | $1,007,176.94 |
DisclosureSEC source: 0001638643-26-000028 · wk-form4_1785879633.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 592,733 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F3 · price: Sale prices for the transactions reported range from $130.18 to $131.17. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 21:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,700 | $129.66 | $868,710.61 |
DisclosureSEC source: 0001638643-26-000028 · wk-form4_1785879633.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 600,433 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 · price: Sale prices for the transactions reported range from $129.17 to $130.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,100 | $127.08 | $393,932.50 |
DisclosureSEC source: 0001638643-26-000026 · wk-form4_1783023256.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 607,133 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F3 · price: Sale prices for the transactions reported range from $126.595 to $127.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 11,900 | $126.09 | $1,500,467.43 |
DisclosureSEC source: 0001638643-26-000026 · wk-form4_1783023256.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 610,233 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 · price: Sale prices for the transactions reported range from $125.59 to $126.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 22:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 8,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001638643-26-000024 · wk-form4_1781216988.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,080 Underlying: Common Stock · 8,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 22:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 4,213 | $121.48 | $511,795.24 |
DisclosureSEC source: 0001638643-26-000024 · wk-form4_1781216988.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 622,133 Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 22:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001638643-26-000024 · wk-form4_1781216988.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 626,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,038 | $132.97 | $138,020.58 |
DisclosureSEC source: 0001638643-26-000022 · wk-form4_1780437841.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 617,567 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F4 · price: Sale prices for the transactions reported range from $132.71 to $133.295. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,062 | $132.22 | $404,842.64 |
DisclosureSEC source: 0001638643-26-000022 · wk-form4_1780437841.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 618,605 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F3 · price: Sale prices for the transactions reported range from $131.71 to $132.70. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,900 | $131.10 | $1,428,983.46 |
DisclosureSEC source: 0001638643-26-000022 · wk-form4_1780437841.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 621,667 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 · price: Sale prices for the transactions reported range from $130.66 to $131.64. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| April 28, 2026 Filed Apr 29, 2026 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,050 | $130.01 | $396,533.86 |
DisclosureSEC source: 0001638643-26-000020 · wk-form4_1777499620.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 632,567 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F3 · price: Sale prices for the transactions reported range from $129.42 to $130.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| April 28, 2026 Filed Apr 29, 2026 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,950 | $128.79 | $895,074.52 |
DisclosureSEC source: 0001638643-26-000020 · wk-form4_1777499620.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 635,617 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 · price: Sale prices for the transactions reported range from $128.41 to $129.325. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| March 27, 2026 Filed Mar 30, 2026 21:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $136.82 | $1,368,162.00 |
DisclosureSEC source: 0001638643-26-000018 · wk-form4_1774907986.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 642,567 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 · price: Sale prices for the transactions reported range from $136.51 to $137.22. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 122,755 | $0.00 Strike: $148.56 | $0.00 |
DisclosureSEC source: 0001638643-26-000014 · wk-form4_1773347089.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,755 Underlying: Common Stock · 122,755 shares Expires 2036-03-10 F3 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% of the options vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 32,815 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001638643-26-000014 · wk-form4_1773347089.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,859 Underlying: Common Stock · 32,815 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 20,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001638643-26-000014 · wk-form4_1773347089.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,044 Underlying: Common Stock · 20,026 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 9,767 | $148.56 | $1,450,985.52 |
DisclosureSEC source: 0001638643-26-000014 · wk-form4_1773347089.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 652,567 Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001638643-26-000014 · wk-form4_1773347089.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $145.71 | $14,571.00 |
DisclosureSEC source: 0001638643-26-000012 · wk-form4_1772487977.xml · nonDerivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 642,308 F2 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,419 | $145.18 | $931,901.43 |
DisclosureSEC source: 0001638643-26-000012 · wk-form4_1772487977.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 642,408 F2 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F4 · price: Sale prices for the transactions reported range from $144.66 to $145.65. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,481 | $144.04 | $501,386.18 |
DisclosureSEC source: 0001638643-26-000012 · wk-form4_1772487977.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 648,827 F2 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F3 · price: Sale prices for the transactions reported range from $143.63 to $144.59. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 38,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001638643-26-000012 · wk-form4_1772487977.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 652,308 F1 · acquired: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2025. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 21:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 115,640 | $0.00 Strike: $66.01 | $0.00 |
DisclosureSEC source: 0001638643-26-000010 · wk-form4_1770412954.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,640 shares Expires 2029-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 21:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 115,640 | $150.00 | $17,346,000.00 |
DisclosureSEC source: 0001638643-26-000010 · wk-form4_1770412954.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 613,912 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 21:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 115,640 | $66.01 | $7,633,396.40 |
DisclosureSEC source: 0001638643-26-000010 · wk-form4_1770412954.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 729,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 74,461 | $143.28 | $10,668,772.08 |
DisclosureSEC source: 0001638643-26-000008 · wk-form4_1770335197.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 613,912 Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 131,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001638643-26-000008 · wk-form4_1770335197.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 688,373 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2023 and March 10, 2024. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares certified for grants made March 10, 2024 will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,968 | $140.24 | $696,725.24 |
DisclosureSEC source: 0001638643-26-000006 · wk-form4_1769725380.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 556,698 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F3 · price: Sale prices for the transactions reported range from $140.00 to $140.57. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,032 | $139.54 | $702,185.91 |
DisclosureSEC source: 0001638643-26-000006 · wk-form4_1769725380.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 561,666 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 · price: Sale prices for the transactions reported range from $138.99 to $139.97. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 00:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 115,640 | $0.00 Strike: $66.01 | $0.00 |
DisclosureSEC source: 0001638643-26-000004 · wk-form4_1769473761.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,640 Underlying: Common Stock · 115,640 shares Expires 2029-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 00:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 115,640 | $135.00 | $15,611,400.00 |
DisclosureSEC source: 0001638643-26-000004 · wk-form4_1769473761.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 566,698 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 00:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 115,640 | $66.01 | $7,633,396.40 |
DisclosureSEC source: 0001638643-26-000004 · wk-form4_1769473761.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 682,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 21:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $124.83 | $1,248,272.00 |
DisclosureSEC source: 0001638643-25-000017 · wk-form4_1767129779.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 566,698 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 · price: Sale prices for the transactions reported range from $124.40 to $125.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 01:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 10,426 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001638643-25-000015 · wk-form4_1765503524.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,070 Underlying: Common Stock · 10,426 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 01:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 4,931 | $121.34 | $598,327.54 |
DisclosureSEC source: 0001638643-25-000015 · wk-form4_1765503524.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 576,698 Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 01:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,426 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001638643-25-000015 · wk-form4_1765503524.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 581,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 21:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,788 | $126.84 | $861,015.71 |
DisclosureSEC source: 0001638643-25-000013 · wk-form4_1764625837.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 571,203 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F3 · price: Sale prices for the transactions reported range from $126.50 to $127.48. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 21:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,212 | $125.91 | $404,428.06 |
DisclosureSEC source: 0001638643-25-000013 · wk-form4_1764625837.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 577,991 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 · price: Sale prices for the transactions reported range from $125.41 to $126.33. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 20:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,022 | $118.82 | $240,258.69 |
DisclosureSEC source: 0001638643-25-000011 · wk-form4_1761768857.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 581,203 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F3 · price: Sale prices for the transactions reported range from $118.61 to $119.06. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 20:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,978 | $119.54 | $953,666.98 |
DisclosureSEC source: 0001638643-25-000011 · wk-form4_1761768857.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 583,225 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F2 · price: Sale prices for the transactions reported range from $119.08 to $120.06. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 20:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,961 | $112.42 | $220,454.25 |
DisclosureSEC source: 0001638643-25-000009 · wk-form4_1759265862.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 591,203 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. F3 · price: Sale prices reported for the transactions reported here range from $112.00 to $112.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.